By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: InSite Vision Is Developing Treatment For Common Eye Disease Blepharitis, For Which There Is Currently No Approved Treatment
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Technology > InSite Vision Is Developing Treatment For Common Eye Disease Blepharitis, For Which There Is Currently No Approved Treatment
Technology

InSite Vision Is Developing Treatment For Common Eye Disease Blepharitis, For Which There Is Currently No Approved Treatment

HerinaAyot
HerinaAyot
Share
3 Min Read
SHARE

InSite Vision Inc. (OTCBB:INSV) has reached an agreement with the U.S.

InSite Vision Inc. (OTCBB:INSV) has reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the design of a Phase 3 clinical trial of AzaSite Plus and DexaSite in patients with blepharitis.

Blepharitis, also known as lid margin disease, is a very common eye disease in the United States and internationally. Characterized by inflammation of the eyelid, blepharitis is a chronic and recurring condition for which there is currently no FDA-approved treatment. The acute flare-ups of this disease can be painful and extremely irritating.

The DOUBle (Dual Ophthalmic agents Used in Blepharitis) study will seek to enroll 900 patients suffering from moderate-to-severe blepharitis in a four-arm trial designed to evaluate both product candidates simultaneously. An SPA is a written agreement with the FDA that the study design and planned analysis of the sponsor’s Phase 3 clinical trial adequately addresses the objectives necessary to support a regulatory submission.

More Read

healthcare delivery GE healthcare
Empathy, Humanity and Design at GE Healthcare
Clinton Applauds Carter Kostler (Age 14) at Health Matters Conference
Meeting The Healthcare Demands of an Aging Population
5 Things to Consider in Your Healthcare Big Data Strategy
What You Need to Know About Mobile Health Apps in 2018

InSite Vision is developing two Phase 3 product candidates formulated with the company’s proprietary DuraSite drug delivery platform for the treatment of blepharitis. AzaSite Plus, combines dexamethasone with the antibiotic AzaSite in DuraSite for the treatment of acute and chronic blepharitis. DexaSite, which combines dexamethasone with DuraSite, is intended to rapidly reduce inflammation in non-bacterial blepharitis.

InSite’s DuraSite sustained delivery technology is a patented synthetic polymer-based formulation designed to extend the residence time of a drug relative to conventional topical therapies. It enables topical delivery of a solution, gel or suspension and can be customized for delivering a wide variety of potential drug candidates. InSite vision is also applying DuraSite to multiple other clinical- and preclinical-stage product candidates to create a portfolio of novel ophthalmic products.

The study will utilize a proprietary quality of life questionnaire developed by InSite Vision in collaboration with leading clinicians and academic experts and the FDA to assess patient treatment experience and longitudinal comfort levels.

“It has been estimated that 34 million people in the United States suffer from blepharitis for which there is currently no approved pharmaceutical treatment,” said Timothy Ruane, Chief Executive Officer of InSite Vision.  “Based on our clinical experience with AzaSite Plus and DexaSite, we believe that the design of the DOUBle Phase 3 program provides us with a unique opportunity to advance two promising products for the treatment of this disease in a single study.”

 

TAGGED:blepharitismedical technology
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

contamination
Batch Failures And The Hidden Costs Of Contamination
Health Infographics
October 21, 2025
Medication Management For Seniors
Simplifying Medication Management For Seniors
Infographics Senior Care
October 21, 2025
Guide To Pursuing a Career in Nursing as a Foreigner in the USA
Collaboration Is the Prescription for Better Patient Care
Health
October 20, 2025
Epidemiological Health Benefits
Personal and Epidemiological Health Benefits of Blood Pressure Management
Health
October 13, 2025

You Might also Like

health IT tricorder
BusinessFinanceMedical DevicesTechnology

Medical Tricorders Fit for Dr. McCoy: XPRIZE Contestants

November 9, 2013

Key Recent Developments in Diabetes Research

January 13, 2012

Role of Montoring Techs in Alarm Notification

February 5, 2014
medical innovation and tech helping people to get healthy
BusinessHospital AdministrationTechnology

Dr. Ryan Shelton Reveals 9 Data-Driven Tips for Optimal Health

February 25, 2021
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?